Figure 1.

Flow-induced release of ATP from ERYs stored in various additive solutions and transferred to various buffer systems prior to introduction to the fluidic device. The green bars, representing our normoglycemic AS-1N transferred into a normoglycemic physiological salt solution (PSSN) maintained ATP release levels above 200 nM throughout storage. ERYs stored in AS-1 and moved to a hyperglycemic PSS (PSSH), represented by the gray bars, released significantly less ATP than AS-1N stored ERYs and continued to decrease throughout storage duration. AS-1 stored ERYs after transfer to PSSN (red bars), initially released statistically equivalent amounts of ATP until day 8, after which the ERYs released less ATP, eventually settling to a value that was statistically equal to the AS-1-PSSH system. This data suggest that the FDA-approved AS-1 storage solution may be damaging to the stored ERYs and that the damage is non-reversible after two weeks of storage. Error bars are ±SEM, n=6 for all, *p<0.05 to AS-1N-PSSN day 1.